GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043161 describes the biological process in which proteins are covalently tagged with ubiquitin and then degraded by the proteasome.
• The process is essential for protein quality control, cell-cycle progression, signal transduction and stress responses.
• Key molecular players include ubiquitin-activating enzymes, ubiquitin-conjugating enzymes, ubiquitin ligases, deubiquitinases and the 26S proteasome.
• Dysregulation of proteasome-mediated ubiquitin-dependent protein catabolic process is linked to cancer, neurodegeneration, sarcopenia and other diseases.
• Experimental dissection of this pathway uses CRISPR knockout, point mutation, knock-in, overexpression, proteomics, transcriptomics and imaging.
• EDITGENE provides end-to-end CRISPR cell model and screening services to study genes in this pathway.
Description
GO:0043161, proteasome-mediated ubiquitin-dependent protein catabolic process, is the controlled destruction of proteins that have been marked by covalent attachment of ubiquitin. This process is central to cellular proteostasis because it removes damaged, misfolded or short-lived regulatory proteins and thereby shapes the proteome. The QuickGO definition states that it comprises the chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome. Researchers study this term because it intersects with nearly every aspect of cell biology, from sperm capacitation and cell-cycle control to therapeutic resistance and tissue wasting. Experimental evidence shows that inhibition or genetic manipulation of components in this pathway alters the stability of key substrates such as MYC, MDM2, DNA-PKcs and others. Consequently, GO:0043161 is a frequent annotation in functional genomics, proteomics and drug-discovery studies.
proteasome-mediated ubiquitin-dependent protein catabolic process At A Glance
| GO ID | GO:0043161 |
|---|---|
| GO term | proteasome-mediated ubiquitin-dependent protein catabolic process |
| Ontology | biological_process |
| Synonym | proteasomal pathway; proteasomal processing; proteasomal ubiquitin-dependent protein breakdown; proteasomal ubiquitin-dependent protein catabolic process; proteasomal ubiquitin-dependent protein catabolism; proteasomal ubiquitin-dependent protein degradation; proteasome pathway |
| Major function | Selective degradation of ubiquitin-tagged proteins by the proteasome |
| Definition | The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome. |
| Related processes | Ubiquitin conjugation, deubiquitination, proteasomal ATPase activity, peptide hydrolysis |
| Cellular location | Cytosol and nucleus, with proteasomes also present in other compartments |
| Example substrates | MYC, MDM2, DNA-PKcs, and many regulatory proteins |
What Is GO:0043161?
In simple terms, GO:0043161 is the process by which a protein is first tagged with a chain of ubiquitin molecules and then delivered to the proteasome, a large protease complex that chops the tagged protein into peptides. The QuickGO definition specifies that the breakdown occurs by hydrolysis of peptide bonds, is initiated by covalent ubiquitin attachment, and is mediated by the proteasome. This distinguishes it from other degradation routes such as autophagy, although crosstalk exists. The term covers the entire sequence from ubiquitin conjugation to proteasomal proteolysis, including the recognition, unfolding, translocation and catalytic steps.
Why Is proteasome-mediated ubiquitin-dependent protein catabolic process Important in Cell Biology?
GO:0043161 is important because it controls the lifetime of proteins that govern cell division, apoptosis, DNA repair, immune signaling and metabolism. Defects in this pathway cause or contribute to cancer, neurodegeneration, muscle atrophy and other disorders, and the pathway is a validated target for drugs such as proteasome inhibitors. Understanding which proteins are degraded, when and how, is therefore a central question in biomedical research.
• Maintains proteostasis by removing damaged or misfolded proteins.
• Regulates cell-cycle progression through timely degradation of cyclins and other regulators.
• Controls oncoprotein stability, including MYC and MDM2.
• Modulates DNA repair by regulating DNA-PKcs levels.
• Influences sperm capacitation and reproductive biology.
• Contributes to muscle wasting and sarcopenia.
• Is a target of natural products and small-molecule inhibitors.
• Can be monitored in plasma exosomes and other clinical samples.
• Crosstalks with autophagy and other degradation systems.
• Provides biomarkers and therapeutic opportunities in cancer and neurodegeneration.
What Happens During proteasome-mediated ubiquitin-dependent protein catabolic process?
Ubiquitin Activation and Conjugation
In simple terms: First, a small tag called ubiquitin is attached to the target protein.
The process begins when ubiquitin is activated by an E1 enzyme, transferred to an E2 conjugating enzyme, and then ligated to a lysine residue on the substrate by an E3 ubiquitin ligase. Repeated rounds produce a polyubiquitin chain that serves as a degradation signal. This step is highly regulated and determines substrate specificity.
Substrate Recognition and Deubiquitination
In simple terms: The ubiquitin tag is recognized, and sometimes it is edited or removed before degradation.
Deubiquitinating enzymes (DUBs) can remove ubiquitin from substrates, reversing or editing the signal. For example, Rpn11 is a proteasome-associated DUB that is required for efficient degradation, and its inhibition blocks protein breakdown. The balance between ubiquitination and deubiquitination controls whether a protein is degraded.
Proteasome Recognition and Translocation
In simple terms: The tagged protein is captured by the proteasome and pulled inside.
The 26S proteasome recognizes polyubiquitin chains and, using ATPases, unfolds and translocates the substrate into the central catalytic chamber. Valosin-containing protein (VCP) participates in delivering ubiquitinated substrates to the proteasome, as shown for DNA-PKcs. This step requires ATP hydrolysis and is tightly coupled to substrate unfolding.
Proteolysis and Peptide Release
In simple terms: Inside the proteasome, the protein is cut into small pieces.
The proteasome's catalytic subunits hydrolyze peptide bonds, releasing short peptides that are further degraded to amino acids. This proteolytic step is the defining feature of GO:0043161 and is mediated by the proteasome's threonine protease active sites. The resulting peptides can be presented by MHC class I molecules or recycled.
Regulation and Cellular Context
In simple terms: The whole process is tuned by cellular signals and can change with stress or disease.
The pathway is regulated by the availability of ubiquitin, the activity of E3 ligases and DUBs, and by proteasome abundance. In sperm capacitation, transcriptomic changes link to this catabolic pathway, indicating physiological regulation. In disease, altered degradation of substrates such as MYC or MDM2 can drive therapeutic resistance or tumor progression.
Key Genes Involved in GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
The following genes and proteins are core components or well-studied substrates of GO:0043161, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| UBB | Ubiquitin precursor | Provides ubiquitin for tagging substrates |
| UBA1 | E1 ubiquitin-activating enzyme | Initiates ubiquitin conjugation |
| UBE2D1 | E2 ubiquitin-conjugating enzyme | Transfers ubiquitin to substrates |
| MDM2 | E3 ubiquitin ligase for p53 | Its own degradation is proteasome-mediated |
| MYC | Oncogenic transcription factor | Stabilized by WEE1, degraded by proteasome |
| DNA-PKcs | DNA repair kinase | Degraded via VCP-proteasome pathway |
| VCP | AAA-ATPase | Regulates proteasome-mediated degradation of DNA-PKcs |
| RPN11 | Proteasome deubiquitinase | Targeted by inhibitors to block degradation |
| PSMD14 | Proteasome subunit | Component of 19S regulatory particle |
| PSMA1 | 20S proteasome subunit | Catalytic core component |
| PSMB5 | 20S proteasome subunit | Catalytic subunit, drug target |
| FOXO1 | Transcription factor | Regulated by Akt/FoxO1 pathway in sarcopenia |
| SIRT1 | Deacetylase | Part of SIRT1/PGC-1α pathway in muscle |
| PGC-1α | Transcriptional coactivator | Mitochondrial biogenesis, muscle health |
| WEE1 | Kinase | Stabilizes MYC, promoting resistance |
| Caspase-3 | Protease | Cleaves pRb and PARP after MDM2 degradation |
| PARP | DNA repair enzyme | Cleaved following proteasome-mediated events |
How Is proteasome-mediated ubiquitin-dependent protein catabolic process Regulated?
The proteasome-mediated ubiquitin-dependent protein catabolic process is regulated at multiple levels. Substrate selection is controlled by E3 ubiquitin ligases and their adaptors, while deubiquitinases such as Rpn11 edit or remove ubiquitin chains to modulate degradation efficiency. In muscle, the Akt/FoxO1 and SIRT1/PGC-1α pathways influence protein breakdown and sarcopenia, indicating hormonal and metabolic control. In cancer, WEE1 kinase stabilizes MYC, thereby altering its proteasomal degradation and promoting therapeutic resistance. Additionally, VCP regulates the degradation of DNA-PKcs in glioma cells, linking the pathway to DNA repair. These examples show that the pathway is not constitutive but dynamically tuned by cellular signals.
proteasome-mediated ubiquitin-dependent protein catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MYC | Esophageal adenocarcinoma, therapeutic resistance | Knockout or point mutation of WEE1 in cancer cell lines |
| MDM2 | Apoptosis, cancer | Overexpression or knockout of MDM2 in tumor cells |
| DNA-PKcs | Glioma, DNA repair | VCP knockout or knockdown in glioma cells |
| FOXO1 | Sarcopenia, muscle wasting | Akt/FoxO1 pathway manipulation in myotubes |
| RPN11 | Cancer, protein degradation | Proteasome deubiquitinase inhibitors in cell lines |
Cancer and Therapeutic Resistance
Proteasome-mediated degradation controls the levels of oncoproteins and tumor suppressors. WEE1 stabilizes MYC to promote therapeutic resistance in esophageal adenocarcinoma, and inhibiting this stabilization may restore sensitivity. MDM2, an E3 ligase for p53, is itself degraded by the proteasome prior to caspase-3-dependent cleavages, linking the pathway to apoptosis. These findings make GO:0043161 a target for anticancer strategies.
Neurodegeneration and Protein Aggregation
Impaired proteasomal degradation contributes to the accumulation of toxic proteins in neurodegenerative diseases. Although direct evidence in the provided citations is limited, the general principle that ubiquitin-proteasome dysfunction underlies proteinopathies is well established. Selective autophagy and ubiquitin-mediated recognition are interconnected, and crosstalk between these systems affects neuronal survival.
Muscle Wasting and Sarcopenia
Juyuanjian attenuates sarcopenia through dual regulation of the Akt/FoxO1 and SIRT1/PGC-1α pathways, which are linked to proteasome-mediated protein breakdown. This suggests that modulating this catabolic process can influence muscle mass and function.
Reproductive Biology and Sperm Capacitation
Sperm capacitation triggers transcriptomic changes linked to the proteasome-mediated ubiquitin-dependent catabolic pathway, highlighting a role in fertilization. This opens research avenues in reproductive medicine.
From proteasome-mediated ubiquitin-dependent protein catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of an E3 ligase affect substrate stability? | CRISPR knockout of the E3 ligase gene |
| Does a point mutation in a substrate alter its degradation? | CRISPR point mutation knock-in of the substrate |
| Does tagging a protein affect its proteasomal targeting? | Knock-in of an epitope tag |
| Does overexpression of a DUB stabilize a substrate? | Overexpression of the DUB |
| Which genes regulate the pathway in a disease context? | CRISPR library screening |
| Can a drug inhibit proteasome-mediated degradation? | Pharmacological inhibition with proteasome inhibitors |
How to Study the proteasome-mediated ubiquitin-dependent protein catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcript abundance | Identify pathway gene expression changes |
| Proteomics | Protein abundance and modifications | Quantify substrate degradation |
| Cycloheximide chase | Protein half-life | Confirm proteasomal degradation |
| Ubiquitin immunoblot | Ubiquitin conjugation | Detect polyubiquitin chains |
| Proteasome activity assay | Catalytic activity | Measure proteasome function |
| Fluorescence microscopy | Localization and dynamics | Visualize degradation in cells |
| CRISPR screen | Gene function | Discover regulators of the pathway |
Transcriptomics and Proteomics
RNA-seq and proteomics can quantify changes in gene expression and protein abundance upon perturbation of the pathway. For example, sperm capacitation triggers transcriptomic changes linked to this catabolic pathway. Plasma exosome multiomics can reveal biomarkers related to proteasome activity.
Ubiquitin and Degradation Assays
Cycloheximide chase assays, ubiquitin immunoblots and proteasome activity assays directly measure degradation rates and ubiquitin conjugation. These methods are essential to confirm that a substrate is degraded via GO:0043161.
Imaging and Localization
Fluorescence microscopy with tagged ubiquitin or proteasome subunits can visualize the pathway in live cells. This helps determine where degradation occurs and how it responds to stimuli.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout or activation screens can identify genes that regulate proteasome-mediated degradation. Such screens are powerful for discovering novel components or drug targets.
How CRISPR Can Be Used to Study GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
Knockout
CRISPR knockout of E3 ligases, DUBs or proteasome subunits can abolish or reduce degradation of specific substrates, revealing their importance in the pathway. For example, VCP knockout affects DNA-PKcs degradation.
Point Mutation
Point mutations can be introduced into ubiquitin acceptor lysines or catalytic residues to dissect mechanism. Such models help determine whether a specific modification is required for degradation.
Knock-in
Knock-in of tagged ubiquitin or substrate proteins allows tracking and affinity purification. This is useful for identifying interaction partners and dynamics.
Overexpression
Overexpression of a substrate or a DUB can overwhelm or alter the pathway, providing gain-of-function insights. For instance, overexpressing Rpn11 can enhance degradation.
How EDITGENE Supports proteasome-mediated ubiquitin-dependent protein catabolic process Research
Researchers studying proteasome-mediated ubiquitin-dependent protein catabolic process-related genes often need to determine whether a candidate gene is causally involved in substrate degradation, disease progression or drug response. EDITGENE provides validated CRISPR cell models and screening services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for proteasome-mediated ubiquitin-dependent protein catabolic process research.
Frequently Asked Questions About proteasome-mediated ubiquitin-dependent protein catabolic process
What is GO:0043161?
GO:0043161 is the Gene Ontology term for proteasome-mediated ubiquitin-dependent protein catabolic process, the degradation of ubiquitin-tagged proteins by the proteasome.
What genes are involved in proteasome-mediated ubiquitin-dependent protein catabolic process?
Key genes include UBB, UBA1, UBE2D1, MDM2, MYC, VCP, RPN11, PSMB5 and others.
How is proteasome-mediated degradation regulated?
It is regulated by E3 ligases, deubiquitinases, ATPases such as VCP, and signaling pathways like Akt/FoxO1.
What diseases are linked to defects in this pathway?
Cancer, neurodegeneration, sarcopenia and reproductive disorders have been linked to altered proteasome-mediated degradation.
What is the role of ubiquitin in this process?
Ubiquitin is covalently attached to substrate proteins, forming a polyubiquitin chain that signals for proteasomal degradation.
How can I study proteasome-mediated degradation in the lab?
Common methods include cycloheximide chase, ubiquitin immunoblots, proteasome activity assays, RNA-seq, proteomics and CRISPR screens.
What is the difference between proteasome and autophagy?
The proteasome degrades individual ubiquitinated proteins, while autophagy engulfs larger structures; crosstalk exists between them.
Which proteins are degraded by the proteasome in cancer?
MYC, MDM2 and DNA-PKcs are examples of proteins whose stability is controlled by the proteasome.
Can CRISPR be used to study this pathway?
Yes, CRISPR knockout, point mutation, knock-in and overexpression models are widely used to dissect the pathway.
What services does EDITGENE offer for this pathway?
EDITGENE provides knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening and bioinformatics services.
Conclusion
GO:0043161, proteasome-mediated ubiquitin-dependent protein catabolic process, is a fundamental biological process that controls protein stability and cellular homeostasis. Its dysregulation contributes to cancer, neurodegeneration, muscle wasting and other conditions, making it a rich area for research and therapeutic targeting. By combining CRISPR cell models, screening and bioinformatics, researchers can uncover new mechanisms and candidates within this pathway.
References
- 1. Caballero-Campo P et al.. 2025. Sperm capacitation triggers transcriptomic changes linked to the proteasome-mediated ubiquitin-dependent catabolic pathway.. Reproduction 170(3) PMID: 40840531
- 2. Thangaretnam K et al.. 2026. WEE1 stabilizes MYC to promote therapeutic resistance in esophageal adenocarcinoma.. Cancer Lett 646:218418 PMID: 41812823
- 3. Yan Y et al.. 2026. Juyuanjian attenuates sarcopenia through dual regulation of the Akt/FoxO1 and SIRT1/PGC-1α pathways.. Phytomedicine 156:158188 PMID: 42068872
- 4. Kraft C et al.. 2010. Selective autophagy: ubiquitin-mediated recognition and beyond.. Nat Cell Biol 12(9):836-41 PMID: 20811356
- 5. Li J et al.. 2018. Epidithiodiketopiperazines Inhibit Protein Degradation by Targeting Proteasome Deubiquitinase Rpn11.. Cell Chem Biol 25(11):1350-1358.e9 PMID: 30146242
- 6. Cho JW et al.. 2001. The levels of MDM2 protein are decreased by a proteasome-mediated proteolysis prior to caspase-3-dependent pRb and PARP cleavages.. J Korean Med Sci 16(2):135-9 PMID: 11306736
- 7. Dong Y et al.. 2025. The multiomics landscape of plasma exosomes in first-episode drug-naïve of schizophrenia.. BMC Psychiatry 25(1):764 PMID: 40770299
- 8. Jiang N et al.. 2013. Valosin-containing protein regulates the proteasome-mediated degradation of DNA-PKcs in glioma cells.. Cell Death Dis 4(5):e647 PMID: 23722536
